secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-07-06T23:59:59+00:00
Accession:  0000950170-23-031899
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences amends Prevail collaboration; milestones cut to $390-395M, cash runway to Q1 2025
--------------------------------------------------------------------------------

- Preclinical and IND-enabling activities shifted to Prevail; manufacturing of initial clinical supply also Prevail's responsibility.
- Maximum milestone payments per licensed product reduced from $420M to $390-395M reflecting changed cost sharing.
- Prevail continues to fund development and commercialization; royalties and nomination fees unchanged.
- Company expects existing cash, operational receipts and credit to fund operations through Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/0000950170-23-031899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/dtil-20230630.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-031899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer